Your session is about to expire
← Back to Search
Chemotherapy
AZD2811 for Small Cell Lung Cancer (TAZMAN Trial)
Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a combination of two drugs, AZD2811 and Durvalumab, to maintain cancer control in adults with advanced small-cell lung cancer who responded well to earlier treatment. AZD2811 stops cancer cell growth, and Durvalumab helps the immune system fight the cancer. Durvalumab has shown survival benefits in various cancers, including non-small cell lung cancer.
Eligible Conditions
- Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Assess safety and tolerability profile in terms safety assessments, adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5.0, and dose modifications
EORTC 13: Lung cancer specific quality of life based on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire - Lung Cancer (QLQ-LC13) v1.0.
EORTC 30: Health related quality of life based on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire - Cancer (QLQ-C30) v3.0.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AZD2811 + DurvalumabExperimental Treatment5 Interventions
Induction:
Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin \& Etoposide)
Maintenance:
AZD2811 + Durvalumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6120
Durvalumab
2017
Completed Phase 2
~3780
AZD2811
2015
Completed Phase 1
~80
Cisplatin
2013
Completed Phase 3
~3120
Etoposide
2010
Completed Phase 3
~2960
Find a Location
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,379 Previous Clinical Trials
288,740,259 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger